Dan Elbaum
Chief Scientific Officer QurAlis
Daniel (Dan) Elbaum, PhD, is a drug discovery and development leader with nearly three decades of experience. He thrives on making new discoveries and connections and has made significant contributions in the fields of oncology, inflammation, and orphan diseases. He has worked in large organizations including Pfizer and Amgen, as well as several start-up companies including Kinetix Pharmacueticals and FoldRx Pharmaceuticals (acquired by Pfizer). He was senior director, chemistry and portfolio management, and co-head of the research and non-clinical development group at Retrophin. To keep abreast of cutting-edge research, he actively maintains close ties with the academic and start-up communities.
Dan earned his PhD and undergraduate degrees in chemistry from Harvard University, and conducted postdoctoral research at the University of Pennsylvania. An inventor on more than 25 patents and an author on more than 15 peer-reviewed publications, Dan is a mentor in the Kindle Mentors Program at Boston University and a longstanding member of the American Chemical Society and the Association for the Advancement of Science
Seminars
- ALS is characterized by the mis-splicing of RNA resulting from TDP-43 LOF
- STMN2 pre-mRNA mis-splicing leads to loss of neuromuscular junctions and motor dysfunction
- The discovery and early development of QRL-201, a splice switching ASO that corrects the mis-splicing of STMN2, will be presented
